Program
HL-1186
A development code.
Its studies are mostly in Pain, Postoperative · Neuralgia, Postherpetic · Neuralgia, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai Yidian Pharmaceutical Technology Development | 55 open or running | phase 2since Aug 11, 2025 | Mar 24, 2025 | Jun 2027phase 2 · NCT07758920 |
| Shanghai Huilun Pharmaceutical | 22 open or running | phase 3since Apr 26, 2026 | Apr 26, 2026 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 24, 2025First study: phase 1 study in Healthy ParticipantsNew to Shanghai Yidian Pharmaceutical Technology DevelopmentShanghai Yidian Pharmaceutical Technology Development · NCT06912295 · 76 planned · China
- Aug 11, 20252 phase 2 studiesShanghai Yidian Pharmaceutical Technology Development · NCT07147049, NCT07159243
- Dec 16, 2025Phase 2 study in Moderate to Severe Acute Postoperative PainShanghai Yidian Pharmaceutical Technology Development · NCT07311369 · 40 planned · China
- Apr 26, 2026Shanghai Huilun Pharmaceutical's first study: phase 3 study in Pain, PostoperativeNew to Shanghai Huilun PharmaceuticalShanghai Huilun Pharmaceutical · NCT07699601 · 330 planned · China
- Jul 12, 2026Phase 3 study in Pain, PostoperativeShanghai Huilun Pharmaceutical · NCT07709598 · 330 planned · China
- Aug 2, 2026Phase 2 study in Neuralgia, PostherpeticShanghai Yidian Pharmaceutical Technology Development · NCT07758920 · 200 planned · China
Ahead
- Jun 2027Primary completion: phase 2 study in Neuralgia, PostherpeticShanghai Yidian Pharmaceutical Technology Development · NCT07758920
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07758920Neuralgia, Postherpetic · China | 2 | Recruiting | Shanghai Yidian Pharmaceutical Technology Development | Jun 2027 | 200 |
| NCT07709598Pain, Postoperative · China | 3 | Recruiting | Shanghai Huilun Pharmaceutical | Oct 2026 | 330 |
| NCT07699601Pain, Postoperative · China | 3 | Recruiting | Shanghai Huilun Pharmaceutical | Oct 2026 | 330 |
| NCT07311369Moderate to Severe Acute Postoperative Pain · China | 2 | Recruiting | Shanghai Yidian Pharmaceutical Technology Development | Feb 2026 | 40 |
| NCT07159243Diabetic Peripheral Neuropathic Pain | 2 | Not yet recruiting | Shanghai Yidian Pharmaceutical Technology Development | Oct 2026 | 180 |
| NCT07147049Moderate to Severe Acute Postoperative Pain · China | 2 | Recruiting | Shanghai Yidian Pharmaceutical Technology Development | Dec 2025 | 72 |
| NCT06912295Healthy Participants · China | 1 | Recruiting | Shanghai Yidian Pharmaceutical Technology Development | Aug 30, 2025 | 76 |
How it is read
Names in the registry
- “HL-1186”, 8 entries
Codes read as this program: HL1186.
Conditions, from the studies’ own filings
- Pain, Postoperative, 4 studies
- Neuralgia, Postherpetic, 1 study
- Neuralgia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.